United States: Federal Circuit Clarifies Scope Of Personal Jurisdiction In Hatch-Waxman Cases

On March 18, 2016, a panel of the Federal Circuit issued its decision in Acorda Therapeutics Inc. v. Mylan Pharms. Inc. and AstraZeneca AB v. Mylan Pharms. Inc., holding that Mylan is subject to specific personal jurisdiction in Delaware by virtue of its filing of a Abbreviated New Drug Application (“ANDA”), coupled with specific plans to sell the generic pharmaceutical products in Delaware. This ruling is likely to be well received by innovator pharmaceutical manufacturers and, if not overturned, would significantly reduce the recent trend of generic companies challenging personal jurisdiction in Hatch-Waxman litigation.

Mylan’s Motions to Dismiss in the District Court of Delaware

In each of the two cases considered by the Federal Circuit, on appeal from the District of Delaware, Mylan had filed a motion to dismiss on the grounds that Delaware lacked both general and specific personal jurisdiction. Personal jurisdiction refers to a court’s ability to rule on issues brought before it and to enforce its decisions against the parties. Broadly speaking, specific personal jurisdiction exists when a defendant has sufficient minimum contacts with a forum state that relate and give rise to the claim at issue, whereas general personal jurisdiction in a forum over a defendant exists independently of any suit-related contacts.

In ruling on Mylan’s motions below, Chief Judge Stark (in Acorda) and Judge Sleet (in AstraZeneca) disagreed about whether Delaware could exercise general personal jurisdiction over Mylan. Their disagreement focused on the impact of the Supreme Court’s 2014 decision in Daimler AG v. Bauman, which limited general jurisdiction to situations where a company’s contact with a forum is so continuous as to render the company “essentially at home” there. In light of Daimler, Chief Judge Stark and Judge Sleet differed on whether Mylan’s registration to do business in Delaware pursuant to a state statute (which required appointment of a registered agent for service of process) constituted a valid form of consent to general personal jurisdiction. Notwithstanding their disagreement, however, both Chief Judge Stark and Judge Sleet found that Delaware could adequately exercise specific personal jurisdiction over Mylan.

The Federal Circuit Majority Panel Opinion

Writing for a Federal Circuit panel that included Judges Newman and O’Malley, Judge Taranto agreed with both Chief Judge Stark and Judge Sleet that Delaware could exercise specific personal jurisdiction. The court noted that Mylan’s ANDA filings “constitute formal acts that reliably indicate plans to engage in marketing of the proposed generic drugs.” The fact that “Mylan intends to direct sales of its drugs into Delaware . . . once it has the requested FDA approval to market them” was of particular importance to the panel. Mylan would “undisputedly” engage in marketing of its ANDA product in Delaware, and Mylan’s planned marketing was “suit-related.” As a result, the court held that “it suffices for Delaware to meet the minimum-contacts requirement in the present cases that Mylan’s ANDA filings and its distribution channels establish that Mylan plans to market its proposed drugs in Delaware and the lawsuit is about patent constraints on such in-State marketing.” 

After finding sufficient minimum contacts, the court went on to review (and ultimately find unpersuasive) the other due process factors that may defeat specific personal jurisdiction: “the burden on the defendant,” “the forum State’s interest in adjudicating the dispute,” “the plaintiff’s interest in obtaining convenient and effective relief,” and “the interstate judicial systems’ interest in obtaining the most efficient resolution of controversies.” With respect to the burden on Mylan, the court found it “modest” because Mylan is a “large generic manufacturer” that has litigated numerous Hatch-Waxman lawsuits in Delaware. With respect to the other factors, the court found that Delaware has an interest in resolving the case because of the future sales of products in the jurisdiction, and that upholding personal jurisdiction in Delaware would serve the interests of the plaintiffs and the judicial system because multiple lawsuits against other generic manufacturers were pending in Delaware on the same patents. Notably, while the general intent to market analysis might arguably support specific personal jurisdiction in virtually any forum nationwide, the majority’s analysis of these more case-specific due process factors focuses on the propriety of Delaware in particular as a forum with sufficient jurisdictional contacts.

Judge O’Malley’s Concurring Opinion

Judge O’Malley authored a separate opinion to discuss the issue of general personal jurisdiction, which the majority Federal Circuit opinion declined to address. Judge O’Malley also wrote to explain that although she concurred with the majority’s judgment finding specific personal jurisdiction over Mylan in Delaware, she did so under a separate legal theory.

With respect to general personal jurisdiction, Judge O’Malley expressed the view that the Supreme Court’s decision in Daimler “did not overrule” a line of Supreme Court cases holding that “a corporation may consent to jurisdiction over its person by choosing to comply with a state’s registration statute.” Applying that rule, Judge O’Malley concluded that Mylan’s compliance with Delaware’s registration statute constituted “voluntary, express consent” to general personal jurisdiction in Delaware. Because a finding that Mylan had consented to broad general personal jurisdiction “would obviate the need” to further consider whether the district courts below had the authority to exercise narrower specific personal jurisdiction, Judge O’Malley noted that she would have ended the court’s jurisdictional discussion at that point. 

Reviewing the majority panel’s opinion, Judge O’Malley agreed that Delaware could properly exercise specific personal jurisdiction over Mylan and accepted the majority’s minimum-contacts analysis. Judge O’Malley suggested, however, that she was not fully persuaded by predicating jurisdiction on Mylan’s future intent to sell generic products. Instead, Judge O’Malley found more persuasive the minimum-contacts analysis set forth in the Supreme Court’s decisions in Calder v. Jones (1984) and Walden v. Fiore (2014). Summarizing Calder, Judge O’Malley explained that courts may exercise specific personal jurisdiction over defendants when those defendants engage in “intentional acts expressly aimed at the forum state, knowing that those acts will harm a potential plaintiff residing in that state.” Judge O’Malley further explained that this test, as clarified by Calder, requires courts to examine “whether the defendant’s conduct connects him to the forum in a meaningful way” to meet due process requirements.

In applying the Calder test to the cases on appeal, Judge O’Malley concluded that both the filing of Mylan’s ANDA and the harm suffered were meaningfully connected to Delaware. As an initial matter, both Acorda and AstraZeneca are Delaware corporations. Mylan, moreover, had “engage[d] in intentional acts expressly aimed at the forum state, knowing that those acts [would] harm a potential plaintiff residing in that state.” Because the “targeted nature” of Mylan’s ANDA filing caused “legally cognizable injuries in Delaware,” specific jurisdiction over Mylan would be proper “based on the ‘effects’” of Mylan’s conduct there.

Looking Ahead

Because the Federal Circuit has exclusive appellate jurisdiction in Hatch-Waxman cases, the panel’s decision will likely have an immediate impact on the choice of forum for plaintiffs filing new Hatch-Waxman suits and the filing of motions to dismiss based on jurisdiction. The decision puts to rest, at least for now, the existing uncertainty about where innovator pharmaceutical companies can bring suit, and the trend of bringing Hatch-Waxman suits in established jurisdictions like the District of Delaware and the District of New Jersey will likely continue.

The decision, however, leaves some questions unanswered. While the majority’s conclusion expands the application of specific personal jurisdiction to ANDA filers, it remains to be seen whether generic companies will be able to successfully challenge jurisdiction in other cases on the basis of the remaining due process factors that would make exercising jurisdiction unreasonable on the facts of a given suit. And, although Judge O’Malley’s concurrence touched on the subject, the majority opinion declined to address the connection between a company’s compliance with state registration statutes and consent to general personal jurisdiction. A recent opinion of the Second Circuit suggested, in contrast to Judge O’Malley, that valid consent to general jurisdiction could no longer, following Daimler, be inferred from registration to do business. See Brown v. Lockheed Martin Corp., No. 14-4083, 2016 U.S. App. LEXIS 2763 (2d Cir. Feb. 18, 2016).

The seeming certainty provided by the panel decision may not last for long. Mylan may seek review of the panel decision by the en banc Federal Circuit, and ultimately may seek review by the Supreme Court. A petition for writ of certiorari would give the Supreme Court an opportunity to review its jurisprudence in Daimler, Calder and Walden, and the effect of that jurisprudence on Hatch-Waxman litigation specifically.

A copy of the Federal Circuit’s decision is available here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.